CRBP — Corbus Pharmaceuticals Holdings, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CRBP
| date | signal | measured base rate |
|---|---|---|
| 2026-07-10 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-05-27 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-05-27 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-06 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-16 | Nicacio Leonardo Viana Chief Medical Officer | Grant or award | 58.3K | 0.00 | 0 |
| 2026-08-11 | Saxena Nishant C Chief Business Officer | Open-market purchase | 2.6K | 9.63 | 25.0K |
| 2026-08-07 | Cohen Yuval Chief Executive Officer | Open-market sale 10b5-1 plan | 17.0K | 10.08 | 171.4K |
| 2026-08-07 | Moran Sean F. Chief Financial Officer | Open-market sale 10b5-1 plan | 12.0K | 10.08 | 121.0K |
| 2026-06-10 | Jenkins John Kenneth Director | Open-market sale 10b5-1 plan | 4.8K | 7.91 | 38.0K |
| 2026-06-10 | Altmeyer Anne Director | Open-market sale 10b5-1 plan | 2.4K | 7.91 | 19.1K |
| 2026-06-10 | Kung Winston Director | Open-market sale 10b5-1 plan | 2.0K | 7.91 | 16.0K |
| 2026-06-03 | Saxena Nishant C Chief Business Officer | Open-market purchase | 9.0K | 7.58 | 68.2K |
| 2026-06-02 | Saxena Nishant C Chief Business Officer | Open-market purchase | 4.5K | 7.33 | 33.0K |
| 2026-05-21 | Saxena Nishant C Chief Business Officer | Grant or award | 58.3K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Cormorant Asset Management, LP | 22.0M | 2.3M |
| ORBIMED ADVISORS LLC | 16.3M | 1.7M |
| Aberdeen Group plc | 12.4M | 1.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.9M | 734.1K |
| CITADEL ADVISORS LLC | 6.8M | 727.1K |
| Prosight Management, LP | 6.5M | 697.1K |
| DIADEMA PARTNERS LP | 4.1M | 440.0K |
| Stonepine Capital Management, LLC | 3.6M | 383.5K |
| ARMISTICE CAPITAL, LLC | 3.4M | 364.0K |
| RENAISSANCE TECHNOLOGIES LLC | 3.3M | 347.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about CRBP
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →